- Home
- PBYI vs DERM Comparison
PBYI vs DERM Comparison
Compare PBYI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- DERM
- Stock Information
- Founded
- PBYI 2010
- DERM 2014
- Country
- PBYI United States
- DERM United States
- Employees
- PBYI N/A
- DERM N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- DERM Health Care
- Exchange
- PBYI Nasdaq
- DERM Nasdaq
- Market Cap
- PBYI 164.3M
- DERM 181.0M
- IPO Year
- PBYI N/A
- DERM 2021
- Fundamental
- Price
- PBYI $3.54
- DERM $7.10
- Analyst Decision
- PBYI Strong Buy
- DERM Strong Buy
- Analyst Count
- PBYI 1
- DERM 2
- Target Price
- PBYI $7.00
- DERM $10.00
- AVG Volume (30 Days)
- PBYI 306.9K
- DERM 178.0K
- Earning Date
- PBYI 07-31-2025
- DERM 08-11-2025
- Dividend Yield
- PBYI N/A
- DERM N/A
- EPS Growth
- PBYI 143.51
- DERM N/A
- EPS
- PBYI 0.77
- DERM N/A
- Revenue
- PBYI $232,709,000.00
- DERM $56,243,000.00
- Revenue This Year
- PBYI N/A
- DERM $28.99
- Revenue Next Year
- PBYI N/A
- DERM $52.61
- P/E Ratio
- PBYI $4.64
- DERM N/A
- Revenue Growth
- PBYI 2.68
- DERM N/A
- 52 Week Low
- PBYI $2.23
- DERM $3.54
- 52 Week High
- PBYI $4.13
- DERM $8.25
- Technical
- Relative Strength Index (RSI)
- PBYI 58.61
- DERM 52.70
- Support Level
- PBYI $3.26
- DERM $6.63
- Resistance Level
- PBYI $3.65
- DERM $7.28
- Average True Range (ATR)
- PBYI 0.14
- DERM 0.38
- MACD
- PBYI 0.01
- DERM 0.03
- Stochastic Oscillator
- PBYI 84.78
- DERM 83.02
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.